Test Catalog

Test Id : CCMGP

Comprehensive Cardiomyopathy Multi-Gene Panel, Blood

Useful For
Suggests clinical disorders or settings where the test may be helpful

Providing a comprehensive genetic evaluation for patients with a personal or family history suggestive of hereditary cardiomyopathy

 

Establishing a diagnosis of a hereditary cardiomyopathy and, in some cases, allowing for appropriate management and surveillance for disease features based on the gene involved

 

Identifying a pathogenic variant within a gene known to be associated with disease that allows for predictive testing of at-risk family members

Genetics Test Information
Provides information that may help with selection of the correct genetic test or proper submission of the test request

This test uses next-generation sequencing to test for variants in the ABCC9, ACTC1, ACTN2, ANKRD1, BRAF, CAV3, CBL, CRYAB, CSRP3, DES, DSC2, DSG2, DSP, DTNA, GLA, HRAS, JUP, KRAS, LAMA4, LAMP2, LDB3, LMNA, MAP2K1, MAP2K2, MYBPC3, MYH6, MYH7, MYL2, MYL3, MYLK2, MYOZ2, MYPN, NEXN, NRAS, PKP2, PLN, PRKAG2, PTPN11, RAF1, RBM20, RYR2, SCN5A, SGCD, SHOC2, SOS1, TAZ, TCAP, TMEM43, TNNC1, TNNI3, TNNT2, TPM1, TTN (excluding the following genomic regions: Chr2(GRCh37):g. 179523879-179524002 and Chr2(GRCh37):g. 179523712-179523835), TTR, and VCL genes.

 

This test uses Sanger sequencing to test for variants in certain exons of the following genes:

MYH6 exon 26

MYH7 exon 27

 

Identification of a pathogenic variant may assist with prognosis, clinical management, familial screening, and genetic counseling.

Prior Authorization is available for this assay.

Highlights

This test includes next-generation sequencing and supplemental Sanger sequencing to evaluate the genes on this panel.

Special Instructions
Library of PDFs including pertinent information and forms related to the test

Method Name
A short description of the method used to perform the test

Custom Sequence Capture and Targeted Next-Generation Sequencing followed by Polymerase Chain Reaction (PCR) and supplemental Sanger Sequencing

NY State Available
Indicates the status of NY State approval and if the test is orderable for NY State clients.

Yes

Reporting Name
Lists a shorter or abbreviated version of the Published Name for a test

Cardiomyopathy Genetic Panel, B

Aliases
Lists additional common names for a test, as an aid in searching

Cardiomyopathy

Dilated Cardiomyopathy (DCM)

Hypertrophic Cardiomyopathy (HCM)

Arrhythmogenic right ventricular cardiomyopathy (ARVC)

Arrhythmogenic right ventricular dysplasia (ARVD)

Left ventricular non-compaction (LVNC)

HCM

DCM

ARVC

ARVD

LVNC

Cardiofaciocutaneous (CFC)

Costello Syndrome (CS)

LEOPARD Syndrome (LS)

Multiple Lentigines

Noonan Syndrome (NS)

ABCC9

ACTC1

ACTN2

ANKRD1

BRAF

CAV3

CBL

CRYAB

CSRP3

DES

DSC2

DSG2

DSP

DTNA

GLA

HRAS

JUP

KRAS

LAMA4

LAMP2

LDB3

LMNA

MAP2K1

MAP2K2

MYBPC3

MYH6

MYH7

MYL2

MYL3

MYLK2

MYOZ2

MYPN

NEXN

NRAS

PKP2

PLN

PRKAG2

PTPN11

RAF1

RBM20

RYR2

SCN5A

SGCD

SHOC2

SOS1

TAZ

TCAP

TMEM43

TNNC1

TNNI3

TNNT2

TPM1

TTN

TTR

VCL

Next Gen Sequencing Test

Specimen Type
Describes the specimen type validated for testing

Whole Blood EDTA

Ordering Guidance

Necessary Information

1. Hereditary Cardiomyopathies and Arrhythmias: Patient Information (T725) is strongly recommended, but not required, to be filled out and sent with the specimen. This information aids in providing a more thorough interpretation of test results. Ordering providers are strongly encouraged to complete the form and send it with the specimen.

2. Include physician name and phone number with specimen.

3. Prior Authorization is available for this assay. Submit the required form with the specimen.

Specimen Required
Defines the optimal specimen required to perform the test and the preferred volume to complete testing

Patient Preparation: A previous bone marrow transplant from an allogenic donor will interfere with testing. Call 800-533-1710 for instructions for testing patients who have received a bone marrow transplant.

Container/Tube: Lavender top (EDTA)

Specimen Volume: 3 mL

Collection Instructions: Send specimen in original tube. Do not aliquot.

Special Instructions
Library of PDFs including pertinent information and forms related to the test

Forms

1. New York Clients-Informed consent is required. Document on the request form or electronic order that a copy is on file. The following documents are available:

-Informed Consent for Genetic Testing (T576)

-Informed Consent for Genetic Testing-Spanish (T826)

2. Comprehensive Cardiomyopathy Multi-Gene Panel Prior Authorization Ordering Instructions

3. Hereditary Cardiomyopathies and Arrhythmias: Patient Information (T725) is recommended.

4. If not ordering electronically, complete, print, and send a Cardiovascular Test Request (T724) with the specimen.

Specimen Minimum Volume
Defines the amount of sample necessary to provide a clinically relevant result as determined by the Testing Laboratory

1 mL

Reject Due To
Identifies specimen types and conditions that may cause the specimen to be rejected

All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.

Specimen Stability Information
Provides a description of the temperatures required to transport a specimen to the performing laboratory, alternate acceptable temperatures are also included

Specimen Type Temperature Time Special Container
Whole Blood EDTA Ambient (preferred)
Refrigerated

Useful For
Suggests clinical disorders or settings where the test may be helpful

Providing a comprehensive genetic evaluation for patients with a personal or family history suggestive of hereditary cardiomyopathy

 

Establishing a diagnosis of a hereditary cardiomyopathy and, in some cases, allowing for appropriate management and surveillance for disease features based on the gene involved

 

Identifying a pathogenic variant within a gene known to be associated with disease that allows for predictive testing of at-risk family members

Genetics Test Information
Provides information that may help with selection of the correct genetic test or proper submission of the test request

This test uses next-generation sequencing to test for variants in the ABCC9, ACTC1, ACTN2, ANKRD1, BRAF, CAV3, CBL, CRYAB, CSRP3, DES, DSC2, DSG2, DSP, DTNA, GLA, HRAS, JUP, KRAS, LAMA4, LAMP2, LDB3, LMNA, MAP2K1, MAP2K2, MYBPC3, MYH6, MYH7, MYL2, MYL3, MYLK2, MYOZ2, MYPN, NEXN, NRAS, PKP2, PLN, PRKAG2, PTPN11, RAF1, RBM20, RYR2, SCN5A, SGCD, SHOC2, SOS1, TAZ, TCAP, TMEM43, TNNC1, TNNI3, TNNT2, TPM1, TTN (excluding the following genomic regions: Chr2(GRCh37):g. 179523879-179524002 and Chr2(GRCh37):g. 179523712-179523835), TTR, and VCL genes.

 

This test uses Sanger sequencing to test for variants in certain exons of the following genes:

MYH6 exon 26

MYH7 exon 27

 

Identification of a pathogenic variant may assist with prognosis, clinical management, familial screening, and genetic counseling.

Prior Authorization is available for this assay.

Clinical Information
Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test

The cardiomyopathies are a group of disorders characterized by disease of the heart muscle. Cardiomyopathy can be caused by inherited, genetic factors or by nongenetic (acquired) causes such as infection or trauma. When the presence or severity of the cardiomyopathy observed in a patient cannot be explained by acquired causes, genetic testing for the inherited forms of cardiomyopathy may be considered. Overall, the cardiomyopathies are some of the most common genetic disorders. The inherited forms of cardiomyopathy include hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), arrhythmogenic right ventricular cardiomyopathy (ARVC or AC), and left ventricular noncompaction (LVNC).

 

The hereditary form of HCM is characterized by left ventricular hypertrophy in the absence of other causes, such as structural abnormalities, systemic hypertension, or physiologic hypertrophy due to rigorous athletic training (athlete's heart). The incidence of HCM in the general population is approximately 1 in 500, and the hereditary form is most often caused by variants in genes encoding the components of the cardiac sarcomere. The clinical presentation of HCM can be variable, even within the same family. HCM can be asymptomatic in some individuals but can also cause life-threatening arrhythmias that increase the risk of sudden cardiac death.

 

DCM is established by the presence of left ventricular enlargement and systolic dysfunction. DCM may present with heart failure with symptoms of congestion, arrhythmias or conduction system disease, or thromboembolic disease (stroke). The incidence of DCM is likely higher than originally reported due to subclinical phenotypes and underdiagnosis, with recent estimates suggesting that DCM affects approximately 1 in every 250 people. After exclusion of nongenetic causes such as ischemic injury, DCM is traditionally referred to as "idiopathic" dilated cardiomyopathy. Approximately 20% to 50% of individuals with idiopathic DCM may have an identifiable genetic cause for their disease. Families with 2 or more affected individuals are diagnosed with familial dilated cardiomyopathy.

 

Arrhythmogenic right ventricular dysplasia (ARVD or AC) is characterized by breakdown of the myocardium and replacement of the muscle tissue with fibrofatty tissue, resulting in an increased risk of arrhythmia and sudden death. Age of onset and severity are variable, but symptoms typically develop in adulthood. The incidence of ARVC is approximately 1 in 1000 to 1 in 2500.

 

LVNC is characterized by left ventricular hypertrophy and prominent trabeculations of the ventricular wall, giving a spongy appearance to the muscle wall. It is thought to be caused by the arrest of normal myocardial morphogenesis. Clinical presentation is highly variable, ranging from no symptoms to congestive heart failure and life-threatening arrhythmias. An increased risk of thromboembolic events is also present with LVNC. Approximately 67% of LVNC is considered familial.

 

Restrictive cardiomyopathy (RCM) is the rarest form of cardiomyopathy and is associated with abnormally rigid ventricular walls. Systolic function can be normal or near normal, but diastolic dysfunction is present. There are several nongenetic causes of RCM, but this condition can be familial as well, with the TNNI3 gene accounting for the majority of inherited cases. The age at presentation for familial RCM ranges from childhood to adulthood, and there is an increased risk of sudden death associated with this condition.

 

Noonan syndrome (NS) is an autosomal dominant disorder of variable expressivity characterized by short stature, congenital heart defects, and characteristic facial dysmorphology. HCM is present in approximately 20% to 30% of individuals affected with NS. There are a number of disorders with significant phenotypic overlap with NS, including Costello syndrome, cardiofaciocutaneous (CFC) syndrome, and multiple lentigines syndrome (formerly called LEOPARD syndrome). NS and related disorders (also called the RASopathies) are caused by variants in genes involved in the RAS-MAPK signaling pathway. In some cases, variants in these genes may cause cardiomyopathy in the absence of other syndromic features.

 

Cardiomyopathy may also be caused by an underlying systemic disease such as a mitochondrial disorder, a muscular dystrophy, or a metabolic storage disorder. In these cases, cardiomyopathy may be the first feature to come to attention clinically. The hereditary forms of cardiomyopathy are most frequently associated with an autosomal dominant form of inheritance; however, X-linked and autosomal recessive forms of disease are also present. In some cases, compound heterozygous or homozygous variants may be present in genes typically associated with autosomal dominant inheritance, often leading to a more severe phenotype. Digenic variants (2 different heterozygous variants at separate genetic loci) in autosomal dominant genes have also been reported to occur in patients with severe disease (particularly HCM and ARVC).

 

The inherited cardiomyopathies display both allelic and locus heterogeneity, whereby a single gene may cause different forms of cardiomyopathy (allelic heterogeneity) and variants in different genes can cause the same form of cardiomyopathy (locus heterogeneity).This comprehensive cardiomyopathy panel includes sequence analysis of 55 genes and may be considered for individuals with HCM, DCM, ARVC, or LVNC, whom have had uninformative test results from a more targeted, disease-specific test. This test may also be helpful when the clinical diagnosis is not clear, or when there is more than 1 form of cardiomyopathy in the family history. It is important to note that the number of variants of uncertain significance detected by this panel may be higher than for the disease-specific panels, making clinical correlation more difficult.

 

Genes included in this gene panel

 

Gene

Protein

Inheritance

Disease association

ABCC9

ATP-binding cassette, subfamily C, member 9

AD

DCM, Cantu syndrome

ACTC1

Actin, alpha, cardiac muscle

AD

CHD, DCM, HCM, LVNC

ACTN2

Actinin, alpha-2

AD

DCM, HCM

ANKRD1

Ankyrin repeat domain-containing protein 1

AD

HCM, DCM

BRAF

V-RAF murine sarcoma viral oncogene homolog B1

AD

Noonan/CFC/Costello syndrome

CAV3

Caveolin 3

AD, AR

HCM, LQTS, LGMD, Tateyama-type distal myopathy, rippling muscle disease

CBL

CAS-BR-M murine ecotropic retroviral transforming sequence homolog

AD

Noonan syndrome-like disorder

CRYAB

Crystallin, alpha-B

AD, AR

DCM, myofibrillar myopathy

CSRP3

Cysteine-and glycine-rich protein 3

AD

HCM, DCM

DES

Desmin

AD, AR

DCM, ARVC, myofibrillar myopathy, RCM with AV block, neurogenic scapuloperoneal syndrome Kaeser type, LGMD

DSC2

Desmocollin

AD, AR

ARVC, ARVC + skin and hair findings

DSG2

Desmoglein

AD

ARVC

DSP

Desmoplakin

AD, AR

ARVC, DCM, Carvajal syndrome

DTNA

Dystrobrevin, alpha

AD

LVNC, CHD

GLA

Galactosidase, alpha

X-linked

Fabry disease

HRAS

V-HA-RAS Harvey rat sarcoma viral oncogene homolog

AD

Costello syndrome

JUP

Junction plakoglobin

AD, AR

ARVC, Naxos disease

KRAS

V-KI-RAS2 Kirsten rat sarcoma viral oncogene homolog

AD

Noonan/CFC/Costello syndrome

LAMA4

Laminin, alpha-4

AD

DCM

LAMP2

Lysosome-associated member protein 2

X-linked

Danon disease

LDB3

LIM domain-binding 3

AD

DCM, LVNC, myofibrillar myopathy

LMNA

Lamin A/C

AD, AR

DCM, EMD, LGMD, congenital muscular dystrophy (see OMIM for full listing)

MAP2K1

Mitogen-activated protein kinase kinase 1

AD

Noonan/CFC

MAP2K2

Mitogen-activated protein kinase kinase 2

AD

Noonan/CFC

MYBPC3

Myosin-binding protein-C, cardiac

AD

HCM, DCM

MYH6

Myosin, heavy chain 6, cardiac muscle, alpha

HCM, DCM

MYH7

Myosin, heavy chain 7, cardiac muscle, beta

AD

HCM, DCM, LVNC, myopathy

MYL2

Myosin, light cahin 2, regulatory, cardiac, slow

AD

HCM

MYL3

Myosin, light chain 3, alkali, ventricular, skeletal, slow

AD, AR

HCM

MYLK2

Myosin light chain kinase 2

AD

HCM

MYOZ2

Myozenin 2

AD

HCM

MYPN

Myopalladin

AD

HCM, DCM

NEXN

Nexilin

AD

HCM, DCM

NRAS

Neuroblastoma RAS viral oncogene homolog

AD

Noonan syndrome

PKP2

Plakophilin 2

AD

ARVC

PLN

Phospholamban

AD

HCM, DCM

PRKAG2

Protein kinase, AMP-activated, noncatalytic, gamma2

AD

HCM, Wolff-Parkinson-White syndrome

PTPN11

Proetin-tyrosine phosphatase, nonreceptor-type, 11

AD

Noonan/CFC/multiple lentigines syndrome

RAF1

V-RAF-1 murine leukemia viral oncogene homolog 1

AD

Noonan/multiple lentigines syndrome

RBM20

RNA-binding motif protein 20

AD

DCM

RYR2

Ryanodine receptor 2

AD

ARVC, CPVT, LQTS

SCN5A

Sodium channel, voltage gated, type V, alpha subunit

AD

Brugada syndrome, DCM, Heart block, LQTS, SSS, SIDS

SGCD

Sarcoglycan, delta

AD, AR

DCM, LGMD

SHOC2

Suppressor of clear, C. elegans, homolog of

AD

Noonan syndrome-like with loose anagen hair

SOS1

Son of sevenless, dropsophil, homolog 1

AD

Noonan syndrome

TAZ

Tafazzin

X-linked

Barth syndrome, LVNC, DCM

TCAP

Titin-cap (telethonin)

AD, AR

HCM, DCM, LGMD

TMEM43

Transmembrane protein 43

AD

ARVC, EMD

TNNC1

Troponin C, slow

AD

HCM, DCM

TNNI3

Troponin I, cardiac

AD, AR

DCM, HCM, RCM

TNNT2

Troponin T2, cardiac

AD

HCM, DCM, RCM, LVNC

TPM1

Tropomyosin 1

AD

HCM, DCM, LVNC

TTN

Titin

AD, AR

HCM, DCM, ARVC, myopathy

TTR

Transthyretin

AD

Transthyretin-related amyloidosis

VCL

Vinculin

AD

HCM, DCM

 

Abbreviations: Hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), arrhythmogenic right ventricular cardiomyopathy (ARVC), left ventricular noncompaction cardiomyopathy (LVNC), restrictive cardiomyopathy (RCM), limb-girdle muscular dystrophy (LGMD), Emory muscular dystrophy (EMD), congenital heart defect (CHD), sudden infant death syndrome (SIDS), long QT syndrome (LQTS), sick sinus syndrome (SSS), autosomal dominant (AD), autosomal recessive (AR)

Reference Values
Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.

An interpretive report will be provided.

Interpretation
Provides information to assist in interpretation of the test results

Evaluation and categorization of variants is performed using the most recent published American College of Medical Genetics and Genomics (ACMG) recommendations as a guideline.(1) Variants are classified based on known, predicted, or possible pathogenicity and reported with interpretive comments detailing their potential or known significance.

 

Multiple in silico evaluation tools may be used to assist in the interpretation of these results. The accuracy of predictions made by in silico evaluation tools is highly dependent upon the data available for a given gene, and predictions made by these tools may change over time. Results from in silico evaluation tools should be interpreted with caution and professional clinical judgment.

Cautions
Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances

Clinical Correlations:

Some individuals who have involvement of 1 or more of the genes on the panel may have a variant that is not identified by the methods performed (eg, promoter variants, deep intronic variants). The absence of a variant, therefore, does not eliminate the possibility of a hereditary cardiomyopathy or a related disorder.

 

Test results should be interpreted in context of clinical findings, family history, and other laboratory data. Misinterpretation of results may occur if the information provided is inaccurate or incomplete.

 

If testing was performed because of a family history of hereditary cardiomyopathy or a related disorder, it is often useful to first test an affected family member. Identification of a pathogenic variant in an affected individual allows for more informative testing of at-risk individuals.

 

Technical Limitations:

Next-generation sequencing may not detect all types of genetic variants. Additionally, rare alterations (ie, polymorphisms) may be present that could lead to false-negative or false-positive results. If results do not match clinical findings, consider alternative methods for analyzing these genes, such as Sanger sequencing or large deletion/duplication analysis. If the patient has had an allogeneic blood or marrow transplant or a recent (ie, less than 6 weeks from time of sample collection) heterologous blood transfusion, results may be inaccurate due to the presence of donor DNA.

 

Reclassification of Variants Policy:

At this time, it is not standard practice for the laboratory to systematically review likely pathogenic variants or variants of uncertain significance that are detected and reported. The laboratory encourages health care providers to contact the laboratory at any time to learn how the status of a particular variant may have changed over time. Consultation with a genetics professional should be considered for interpretation of this result.

 

A list of benign and likely benign variants detected for this patient is available from the laboratory upon request.

 

Contact the laboratory if additional information is required regarding the transcript or human genome assembly used for the analysis of this patient's results.

Clinical Reference
Recommendations for in-depth reading of a clinical nature

1. Richards S, Aziz N, Bale S, et al: Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015 May;17(5):405-424

2. Hershberger RE, Morales A: Dilated cardiomyopathy overview. In: Adam MP, Ardinger HH, Pagon RA, et al, eds. GeneReviews [Internet]. University of Washington, Seattle; 2007. Updated July 29, 2021. Accessed September 21, 2021. Available at www.ncbi.nlm.nih.gov/books/NBK1309/

3. Cirino AL, Ho C: Hypertrophic cardiomyopathy overview. In: Adam MP, Ardinger HH, Pagon RA, et al, eds. GeneReviews [Internet]. University of Washington, Seattle; 2008. Updated July 8, 2021. Accessed September 21, 2021. Available at www.ncbi.nlm.nih.gov/books/NBK1768/

4. McNally E, MacLeod H, Dellefave-Castillo L: Arrhythmogenic right ventricular dysplasia/cardiomyopathy. In: Adam MP, Ardinger HH, Pagon RA, et al, eds. GeneReviews [Internet]. University of Washington, Seattle; 2005. Updated May 25, 2017. Accessed June 2018. Available at www.ncbi.nlm.nih.gov/books/NBK1131/

5. Allanson JE, Roberts AE: Noonan syndrome. In: Adam MP, Ardinger HH, Pagon RA, et al, eds. GeneReviews [Internet]. University of Washington, Seattle; 2001. Updated August 8, 2019. Accessed September 21, 2021. Available at www.ncbi.nlm.nih.gov/books/NBK1124/

6. Ichida F: Left ventricular noncompaction. Circ J. 2009;73(1):19-26

7. Callis TE, Jensen BC, Weck KE, Willis MS: Evolving molecular diagnostics for familial cardiomyopathies: at the heart of it all. Expert Rev Mol Diagn. 2010 April:10;3:329-351

8. Ackerman MJ, Priori SG, Willems S, et al: HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies. Heart Rhythm. 2011;8:1308-1339

9. Hoedemaekers YM, Caliskan K, Michels M, et al: The importance of genetic counseling, DNA diagnostics, and cardiologic family screening in left ventricular noncompaction cardiomyopathy. Circ Cardiovasc Genet. 2010;3:232-239

Special Instructions
Library of PDFs including pertinent information and forms related to the test

Method Description
Describes how the test is performed and provides a method-specific reference

Next-generation sequencing (NGS) is performed using an Illumina instrument with paired-end reads. The DNA is prepared for NGS using a custom Agilent SureSelect Target Enrichment System. Data is analyzed with a bioinformatics software pipeline. Supplemental and confirmatory Sanger sequencing are performed when necessary.(Unpublished Mayo method)

 

Genes analyzed: ABCC9, ACTC1, ACTN2, ANKRD1, BRAF, CAV3, CBL, CRYAB, CSRP3, DES, DSC2, DSG2, DSP, DTNA, GLA, HRAS, JUP, KRAS, LAMA4, LAMP2, LDB3, LMNA, MAP2K1, MAP2K2, MYBPC3, MYH6, MYH7, MYL2, MYL3, MYLK2, MYOZ2, MYPN, NEXN, NRAS, PKP2, PLN, PRKAG2, PTPN11, RAF1, RBM20, RYR2, SCN5A, SGCD, SHOC2, SOS1, TAZ, TCAP, TMEM43, TNNC1, TNNI3, TNNT2, TPM1, TTN (excluding the following genomic regions: Chr2(GRCh37):g. 179523879-179524002 and Chr2(GRCh37):g. 179523712-179523835), TTR, and VCL.

PDF Report
Indicates whether the report includes an additional document with charts, images or other enriched information

No

Day(s) Performed
Outlines the days the test is performed. This field reflects the day that the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time before the test is performed. Some tests are listed as continuously performed, which means that assays are performed multiple times during the day.

Monday

Report Available
The interval of time (receipt of sample at Mayo Clinic Laboratories to results available) taking into account standard setup days and weekends. The first day is the time that it typically takes for a result to be available. The last day is the time it might take, accounting for any necessary repeated testing.

4 to 6 weeks after prior authorization approved

Specimen Retention Time
Outlines the length of time after testing that a specimen is kept in the laboratory before it is discarded

Extracted DNA: 2 months

Performing Laboratory Location
Indicates the location of the laboratory that performs the test

Rochester

Fees
Several factors determine the fee charged to perform a test. Contact your U.S. or International Regional Manager for information about establishing a fee schedule or to learn more about resources to optimize test selection.

  • Authorized users can sign in to Test Prices for detailed fee information.
  • Clients without access to Test Prices can contact Customer Service 24 hours a day, seven days a week.
  • Prospective clients should contact their Regional Manager. For assistance, contact Customer Service.

Test Classification
Provides information regarding the medical device classification for laboratory test kits and reagents. Tests may be classified as cleared or approved by the US Food and Drug Administration (FDA) and used per manufacturer instructions, or as products that do not undergo full FDA review and approval, and are then labeled as an Analyte Specific Reagent (ASR) product.

This test was developed, and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information
Provides guidance in determining the appropriate Current Procedural Terminology (CPT) code(s) information for each test or profile. The listed CPT codes reflect Mayo Clinic Laboratories interpretation of CPT coding requirements. It is the responsibility of each laboratory to determine correct CPT codes to use for billing.

CPT codes are provided by the performing laboratory.

81439

Prior Authorization
Prior Authorization may be required by your insurance carrier.

Insurance preauthorization is available for this testing; forms are available.

 

Patient financial assistance may be available to those who qualify. Patients who receive a bill from Mayo Clinic Laboratories will receive information on eligibility and how to apply.

LOINC® Information
Provides guidance in determining the Logical Observation Identifiers Names and Codes (LOINC) values for the order and results codes of this test. LOINC values are provided by the performing laboratory.

Test Id Test Order Name Order LOINC Value
CCMGP Cardiomyopathy Genetic Panel, B In Process
Result Id Test Result Name Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
36801 Gene(s) Evaluated 48018-6
36802 Result Summary 50397-9
36803 Result Details 82939-0
36804 Interpretation 69047-9
36941 Additional Information 48767-8
36942 Method 85069-3
36943 Disclaimer 62364-5
36805 Reviewed by 18771-6

Test Setup Resources

Setup Files
Test setup information contains test file definition details to support order and result interfacing between Mayo Clinic Laboratories and your Laboratory Information System.

Excel | Pdf

Sample Reports
Normal and Abnormal sample reports are provided as references for report appearance.

Normal Reports | Abnormal Reports

SI Sample Reports
International System (SI) of Unit reports are provided for a limited number of tests. These reports are intended for international account use and are only available through MayoLINK accounts that have been defined to receive them.

SI Normal Reports | SI Abnormal Reports

Test Update Resources

Change Type Effective Date
Obsolete Test 2022-12-15